Jeffrey Sum-Lung Wong1, Yawen Dong1, Vikki Tang1, Thomas Leung2, Cynthia S Y Yeung3, Anna Tai4, Ada Law5, Tracy Shum6, Gerry Gin-Wai Kwok1, Bryan Cho-Wing Li1, Roland Leung1, Joanne Chiu1, Ka-Wing Ma7, Wong-Hoi She7, Josephine Tsang1, Tan-To Cheung7, Thomas Yau1. 1. Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China. 2. Department of Medicine, Hong Kong Sanatorium and Hospital, Hong Kong, China. 3. Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China. 4. Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China. 5. Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China. 6. Department of Clinical Oncology, Princess Margaret Hospital, Hong Kong, China. 7. Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Abstract
(1) Background: Cabozantinib is approved in sorafenib-exposed advanced hepatocellular carcinoma (aHCC). We evaluated the real-life pattern of use, efficacy, and tolerability of cabozantinib in aHCC. (2) Methods: This territory-wide study included consecutive aHCC patients who received cabozantinib between February 2018 and September 2020 in Hong Kong. The objective response rate (ORR), disease control rate (DCR), overall survival (OS), and adverse events (AE) were assessed. (3) Results: Overall, 42 patients were included. Approximately 83.3% had Child-Pugh A cirrhosis. About 64.3% received cabozantinib as a single agent, and the remaining 35.7% received cabozantinib as an add-on to immune checkpoint inhibitors (ICIs). For single-agent patients, the median follow-up was 6.7 months. The ORR was 3.7%, DCR was 44.4%, and the median OS was 8.28 months. About 74.1% of patients experienced any AEs with 7.4% having grade ≥3 AEs. Among patients who received prior ICIs (n = 16), the ORR was 6.3%, and the median OS was 8.28 months. An exploratory analysis of patients who received cabozantinib as an add-on to ICIs showed an ORR of 6.7% and a median OS of 15.1 months, with 73.3% having any AE and 13.3% having grade ≥3 AEs. (4) Conclusions: Cabozantinib had good anti-tumor activity, survival benefits, and acceptable tolerability in real-life aHCC patients.
(1) Background: Cabozantinib is approved in sorafenib-exposed advanced hepatocellular carcinoma (aHCC). We evaluated the real-life pattern of use, efficacy, and tolerability of cabozantinib in aHCC. (2) Methods: This territory-wide study included consecutive aHCC patients who received cabozantinib between February 2018 and September 2020 in Hong Kong. The objective response rate (ORR), disease control rate (DCR), overall survival (OS), and adverse events (AE) were assessed. (3) Results: Overall, 42 patients were included. Approximately 83.3% had Child-Pugh A cirrhosis. About 64.3% received cabozantinib as a single agent, and the remaining 35.7% received cabozantinib as an add-on to immune checkpoint inhibitors (ICIs). For single-agent patients, the median follow-up was 6.7 months. The ORR was 3.7%, DCR was 44.4%, and the median OS was 8.28 months. About 74.1% of patients experienced any AEs with 7.4% having grade ≥3 AEs. Among patients who received prior ICIs (n = 16), the ORR was 6.3%, and the median OS was 8.28 months. An exploratory analysis of patients who received cabozantinib as an add-on to ICIs showed an ORR of 6.7% and a median OS of 15.1 months, with 73.3% having any AE and 13.3% having grade ≥3 AEs. (4) Conclusions: Cabozantinib had good anti-tumor activity, survival benefits, and acceptable tolerability in real-life aHCC patients.
Authors: Robin Kate Kelley; Jennifer W Oliver; Saswati Hazra; Fawzi Benzaghou; Thomas Yau; Ann-Lii Cheng; Lorenza Rimassa Journal: Future Oncol Date: 2020-06-03 Impact factor: 3.404
Authors: Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo Journal: Lancet Oncol Date: 2018-06-03 Impact factor: 41.316
Authors: Malgorzata Borowiak; Alistair N Garratt; Torsten Wüstefeld; Michael Strehle; Christian Trautwein; Carmen Birchmeier Journal: Proc Natl Acad Sci U S A Date: 2004-07-12 Impact factor: 11.205
Authors: Qingfeng Xiang; Weiqiang Chen; Meng Ren; Jingnan Wang; Hongwu Zhang; David Y B Deng; Lei Zhang; Changzhen Shang; Yajin Chen Journal: Clin Cancer Res Date: 2014-04-03 Impact factor: 12.531
Authors: Su Jin Lee; Jeeyun Lee; Insuk Sohn; Mao Mao; Wang Kai; Cheol-Keun Park; Ho Yeong Lim Journal: Anticancer Res Date: 2013-11 Impact factor: 2.480
Authors: Thomas Yau; David Tai; Stephen Lam Chan; Yi-Hsiang Huang; Su Pin Choo; Chiun Hsu; Tan To Cheung; Shi-Ming Lin; Wei Peng Yong; Joycelyn Lee; Thomas Leung; Tracy Shum; Cynthia S Y Yeung; Anna Yin-Ping Tai; Ada Lai Yau Law; Ann-Lii Cheng; Li-Tzong Chen Journal: Liver Cancer Date: 2022-06-17 Impact factor: 12.430